Early interferon therapy reduces secondary myelofibrosis risk in young ET and PV patients. Cytoreductive drugs do not lower thrombotic event risk in young patients. Elevated white blood cell counts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback